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Abstract
Background: Hypertriglyceridemia is associated with increased risk for cardiovascular diseases and type 2 diabetes
(T2D). Angiopoietin like proteins particularly 3, 4 and recently 8 are well established regulators of plasma triglyceride
level through regulating the activity of lipoprotein lipase. Plasma level and association between ANGPTL3, 4 and 8
is not well established in human subjects. This study was designed to establish the level of these proteins in plasma
and adipose tissues and investigate the association between ANGPTL8 with ANGPTL3 and 4 in T2D and non-
diabetics subjects.
Methods: A total of 235 subjects were enrolled in this study, 144 non-diabetics and 91 T2D. ANGPTL 3, 4 and 8 levels
were measured in plasma by ELISA and using real time RT-PCR in adipose tissues.
Results: In this study, we showed that ANGPTL3, 4 and 8 were higher in T2D subjects. Dividing the non-diabetic
subjects according to their BMI showed higher level of ANGPTL3, 4 and 8 in obese subjects compared to non-obese
subjects. No significant difference was observed between the T2D subjects. ANGPTL8 was showed positive correlation
with ANGPTL3 in the non-diabetic subjects in the non-obese (r = 0.2437, p-Value = 0.0543) and obese subjects
(r = 0.418, p-Value = 0.0125). No association was observed in the T2D subjects. On the other hand, ANGPTL4
was positively associated with the obese subjects in both the non-diabetics (r = 0.3322, p-Value = 0.0316) and
the obese T2D subjects (r = 0.3161, p-Value = 0.0211).
Conclusion: In conclusion, our data shows that ANGPTL3, 4 and 8 are increased in obesity and T2D. ANGPTL8
associates with ANGPTL3 in the non-diabetic subjects while it associated more with ANGPTL4 in the obese and
T2D subjects. Taken together, this data highlight the role of these proteins in metabolic diseases and how they
interact with each other’s under different physiological and pathophysiological conditions.
Background
Hypertriglyceridemia has been linked to increased inci-
dents of cardiovascular disease and Type 2 diabetes
(T2D) [1, 2]. Triglycerides (TG) are essential to human
life as they provide energy and store excess energy in the
body [3, 4]. They circulate in blood as lipoprotein mole-
cules such as chylomicrons that are formed from dietary
TG or VLDL, which are produced by the liver under
fasting state [5, 6]. Chylomicrons and VLDL mediate the
transfer of TG to various tissues for storage or oxidation
to produce energy [3, 4]. The key enzyme involved in
the breakdown of TG to generate free fatty acids (FFA)
is lipoprotein lipase (LPL) [7, 8]. LPL activity regulates
TG clearance and its availability for other tissues such as
heart and muscle. LPL hyperactivity has been associated
with decreased plasma TG level and decreased cardio-
vascular risks while its loss of function resulted in severe
hypertriglyceridemia [7, 8]. As a result its cellular func-
tion is tightly regulated to accommodate the need of
various tissues for TG and to maintain physiological TG
blood level [7, 8].
One of the key regulators of LPL are members of
the angiopoietin-like protein (ANGPTL) family mainly
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ANGPTL3, 4 and 8 [7, 8]. Seven members have been trad-
itionally assigned to the ANGPTL family due to their simi-
larity to angiopoietin proteins [9, 10]. All members have
N-terminal coiled-coil domain as well as a carboxyl-
terminal fibrinogen-like domain, except the recently added
ANGPTL8 family member which lacks the fibrinogen-like
domain [9–12]. The role of ANGPTL3 and 4 in regulating
LPL activity has been well established. ANGPTL3 is
produced by the liver then it is proteolytically cleaved by
proprotein convertases to generate an active N-terminal
domain that acts as an inhibitor of LPL activity [12, 13].
One study showed that loss of function mutations identi-
fied in ANGPTL3 associated with decreased VLDL, LDL,
HDL and TG [14]. This was also linked to a recessive
disorder disease termed familial combined hypobetali-
poproteinemia [14, 15]. ANGPTL4 is another potent
inhibitor of LPL activity that is induced in the fasting
state by the PPAR (peroxisome proliferator-activated
receptor) transcription factor [7]. Similar to ANGPTL3,
the N-terminal domain of ANGPTL4 is cleaved by pro-
protein convertases and act as an inhibitor of LPL activity
[7]. The inhibition of LPL activity occurs through the dir-
ect binding of the cleaved ANGPTL4 to LPL protein,
which in turn inhibits its dimerization rendering the LPL
enzyme inactive [8, 16]. Recent data has also linked loss of
function mutations in ANGPTL4 to reduced incidences of
Coronary heart disease [17, 18]. Due to their role in
regulating LPL activity and the fact that many genome
wide association studies has linked them to dyslipid-
emia, ANGPTL3 and 4 are being explored as drug tar-
gets for metabolic diseases [16]. Specific monoclonal
antibodies targeting ANGPTL3 and 4 has been shown
to decrease plasma lipid content [16].
ANGPTL8 on the other hand has been shown to regulate
LPL activity through its interaction with the N-terminal do-
main of ANGPTL3, which facilitates its cleavage [12, 19].
ANGPTL8 is mainly expressed in the liver, white adipose
tissue as well as brown adipose tissue [12, 19–21]. It has
been initially shown to be induced by feeding and reduced
by fasting [20, 21]. Similar to ANGPTL3 and 4, sequence
variation in ANGPTL8 has been associated with decreased
LDL and HDL lipid profile [12]. Quagliarini et al. showed
that rs2278426, which represents a non-synonymous amino
acid change from Arginine (R) to tryptophan (W) at amino
acid 59, was associated with lower LDL-C and HDL-C in
various ethnic groups [12]. We have also showed that this
variant was associated with higher plasma glucose in Arabs
[12]. Collectively, ANGPTL3, 4 and 8 are shown to play an
important role in the regulation of LPL activity. Therefore,
further research on the collective role of these three pro-
teins in humans is critical to enhance our understanding of
lipid metabolism. As a result we designed this study to
investigate the possible changes in the expression levels
in circulation and adipose tissue in both diabetic and
non-diabetic subjects. In addition, we investigated the
possible association between ANGPTL8 and ANGPTL3
and 4 in this population to better understand their
physiological role.
Methods
Study population and ethical statement
In the present study, a total of 144 non-diabetics and 91
T2D subjects were recruited at Dasman Diabetes Institute.
Based on the Body Mass Index (BMI) the non-diabetic
subjects were split into a total of 82 non-obese subjects
(19.5 and ≤ BMI < 30 kg/m2) and 62 obese subjects (30 ≤
BMI < 40 kg/m2). On the other hand, 27 T2D subjects
were classified as non-obese and 64 were obese. The for-
mula used to calculate BMI is the standard BMI formula:
body weight (in kilograms)/height (in meters squared). All
subjects signed a written informed consent before their
participation in the study, which was approved by the
Ethical Review Board of Dasman Diabetes Institute and
abiding with the guideline ethical declaration of Helsinki.
Morbidly obese subjects (BMI >40 kg/m2) as well as sub-
jects with prior major illness or taking any medication
and/or supplement known to influence the body compos-
ition or bone mass were excluded from the study [22].
Blood collection, anthropometric and biochemical
measurements
Blood samples were collected in vacutainer EDTA tubes
that were centrifuged to collect plasma samples which in
turn were aliquoted and stored at −80 °C until assayed
as described previously [22–24]. Subcutaneous adipose
tissue (SAT) biopsies were obtained from the periumbilical
area by surgical biopsy after a local anaesthesia as de-
scribed previously [22]. Following the surgical extraction
of SAT tissues they were rinsed in cold PBS and stored at
−80 °C in Allprep until assayed.
The anthropometric and biochemical measurements
were collected as follows: an average of three blood pres-
sure readings measured using an Omron HEM-907XL
Digital sphygmomanometer were taken with a 5–10 min
rest between each reading. Whole-body composition was
determined by dual-energy radiographic absorptiometry
device (Lunar DPX, Lunar radiation, Madison, WI). Fasting
blood Glucose (FBG) triglyceride (TG), total cholesterol
(TC), low density lipoprotein (LDL) and high density lipo-
protein (HDL) were measured on the Siemens Dimension
RXL chemistry analyzer (Diamond Diagnostics, Holliston,
MA). Glycated hemoglobin (HbA1C) was determined using
the VariantTM device (BioRad, Hercules, CA).
ANGPTL8 ELISA
ANGPTL8 level was measured in plasma as described
previously [23, 25, 26]. Plasma samples were thawed on
ice and centrifuged at 10000xg for 5 min at 4 °C to
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remove any debris as described previously [22–24]. Re-
peated freeze thaw cycles were avoided. ANGPTL8 level
was determined using the ELISA kit from Wuhan EIAAB
Science co (catalogue number E1164H) as described previ-
ously [23, 25, 26]. No significant cross reactivity with other
proteins was observed. Intra-assay coefficients of variation
(CV) were 2.1 to 4.6 %, while the inter-assay coefficients
of variation were 7.3 to 9.6 %.
ANGPTL3 and 4 ELISA
Plasma levels of ANGPTL3 and 4 were assessed using
the multiplexing immunobead array platform accord-
ing to the manufacturer instructions (R & D systems).
The data was processed using the Bio-Plex manager
software version 6 (Bio-Rad) using five-parametric
curve fitting. Intra plate CV ranged from 7.0 to 12 %,
while inter plate CV was <14 %. Samples were mea-
sured using reagents from the same lot to avoid lot- to
lot variations.
Measurement of gene expression by quantitative Real
Time-PCR (qRT-PCR)
Total RNA was extracted from frozen SAT tissues using
RNeasy Lipid Tissue Mini Kit according to manufac-
turer’s protocol (Qiagen, Inc., Valencia, CA). Total RNA
was isolated from adipose tissue biopsies of obese non-
diabetic (n = 8) and obese diabetic (n = 8). The cDNA was
prepared from total RNA sample using High Capacity
cDNA Reverse Transcription Kits (Applied Biosystems,
Foster City, CA). QRT-PCR was performed on Rotor-Disc
100 system using SYBR Green normalized to Gapdh (Qia-
gen, Inc., Valencia, CA). The following primer sequences
were used for gene expression quantification: ANGPTL3
forward: TCTCCAGAGCCAAAATCAAGAT and Reverse:
TTTCACTGGTTTGCAGCGAT. ANGPTL4 forward: CA
GTCCTCGCACCTGGAA and reverse: GCCAGGACATT
CATCTCGTC. ANGPTL8 forward: AATCTGCCTGGAT
GGAACTG and reverse: CTGCGTCTGTCTCTGCTCTG.
GAPDH forward: AACTTTGGCATTGTGGAAGG-3′
and reverse: TGTGAGGGAGATGCTCAGTG. Relative
expression was assessed by using the ΔΔCT method [27].
Statistical analysis
Comparisons between non-obese and obese subjects
were made by Student’s t-test. Spearman’s correlation
coefficients were estimated to determine associations of
ANGPTL8 with ANGPTL3 and/or 4. All data are re-
ported as mean ± standard deviations. Statistical assess-
ments were two-sided and considered to be significant
when p-Value < 0.05. All analyses were performed using
SAS (version 9.2; SAS Institute).
Results
Study population characteristics
Clinical and biochemical characteristics of the non-
diabetics and T2D subjects are shown in Table 1. Our
population was made of 235 subjects divided into 144
non-diabetic and 91 T2D subjects. The average age of
the non-diabetic subjects was 41.76 ± 11.81 years while
the average age of T2D subjects were 52.89 ± 9.32 years.
T2D subjects had significantly higher BMI, percent body
fat, TG, TC, HDL, FBG, and HbA1C (p-Value < 0.05)
(Table 1). T2D subjects had significantly higher level of
ANGPTL8 (2520.14 ± 155.31 pg/ml) compared to the
non-diabetics (936.78 ± 55.43 pg/ml, p-Value < 0.001).
ANGPTL4 was also higher in T2D subjects (203.78 ±
11.68 ng/ml compared to 144.47 ± 4.47 ng/ml for the
non-diabetics) (p-Value < 0.001). A similar trend was also
observed for ANGPTL3 in T2D 69.17 ± 3.07 ng/ml and
62.39 ± 1.89 ng/ml for the non-diabetics (p-Value = 0.06)
Table 1.
Plasma level of ANGPTL3, 4 and 8 in the whole
population
Plasma level of all markers was examined between non-
diabetic and T2D subjects. Overall, plasma level of
ANGPTL3, 4 and 8 was higher in the T2D subjects.
ANGPTL3 plasma level in the non-diabetic subjects was
62.39 ± 1.89 ng/mL compared to 69.17 ± 3.07 in the T2D
subjects (p-Value = 0.062) Fig. 1a. ANGPTL4 plasma
level was 144.47 ± 4.47 ng/mL in the non-diabetic subjects
vs 203.78 ± 11.68 ng/mL in the T2D subjects (p-Value
<0.0001) Fig. 1b. Finally, ANGPTL8 level was also higher
in the T2D subjects 2520.14 ± 155.31 pg/mL compared
to 936.78 ± 55.43 pg/mL in the non-diabetic subjects
(p-Value <0.0001) Fig. 1c.
Table 1 Characteristics of the non-diabetic and diabetic subjects
included in this study







Age (years) 41.76 ± 11.81 52.89 ± 9.32 <0.000
BMI (kg/m2) 29.06 ± 5.87 31.64 ± 4.30 <0.000
Percent Body Fat 34.56 ± 6.68 36.27 ± 5.56 0.023
TC (mmol/L) 5.07 ± 0.93 4.94 ± 1.29 0.282
HDL (mmol/L) 1.27 ± 0.38 1.19 ± 0.46 0.087
LDL (mmol/L) 3.20 ± 0.86 3.02 ± 1.26 0.110
TG (mmol/L) 1.29 ± 0.90 1.87 ± 2.18 0.003
FBG (mmol/L) 5.32 ± 1.01 8.64 ± 3.31 <0.000
HbA1C (DCCT%) 5.67 ± 0.85 7.98 ± 1.85 <0.000
ANGPTL8 pg/ml 936.78 ± 55.43 2520.14 ± 155.31 <0.000
ANGPTL4 ng/ml 144.47 ± 4.47 203.78 ± 11.68 <0.000
ANGPTL3 ng/ml 62.39 ± 1.89 69.17 ± 3.07 0.062
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Plasma level of ANGPTL3, 4 and 8 in T2D subjects
In the T2D subjects, the circulation level of ANGPTL3,
4 and 8 were higher in the obese subjects however, it did
not reach statistical significance. ANGPTL3 level in the
non-obese subjects was 67.59 ± 5.18 ng/ml compared to
70.04 ± 3.84 ng/ml in the obese subjects (p-Value =
0.7055) Fig. 2a. ANGPTL4 level in non-obese subjects was
191.70 ± 19.52 ng/ml vs 210.50 ± 14.62 ng/ml in the obese
subjects (p-Value =0.443) Fig. 2b. Finally, ANGPTL8 level
in the non-obese subjects was 2185.48 ± 283.58 pg/ml
compared to 2661.32 ± 184.19 pg/ml for the obese sub-
jects (p-Value = 0.1628) Fig. 2c.
Plasma level of ANGPTL3, 4 and 8 in the non-diabetic
subjects
Overall, plasma level of ANGPTL3, 4 and 8 were higher
in T2D subjects compared to non-diabetics as shown in
Fig. 1a, b and c. To better understand the possible asso-
ciation of these protein with obesity, the non-diabetics
and T2D subjects were further divided into obese and
non-obese groups. ANGPTL3 level was significantly higher
Fig. 1 Circulation level of ANGPTL3, 4 and 8 in all subjects measured
by ELISA. a Circulation level of ANGPTL3 in non-diabetic vs. T2D
subjects in all subjects. b Plasma level of ANGPTL4 in non-diabetic
vs. T2D subjects in all subjects. c Circulation level of ANGPTL8 in
non-diabetic vs. T2D subjects in all subjects
Fig. 2 Circulation level of ANGPTL3, 4 and 8 T2D subjects in
accordance to their obesity level measured by ELISA. a Circulation
level of ANGPTL3 in non-obese vs obese T2D subjects. b Plasma
level of ANGPTL4 in non-obese vs obese T2D subjects. c Plasma level
of ANGPTL8 measured by ELISA T2D subjects
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in the obese subjects compared to the non-obese subjects
(67.30 ± 2.96 ng/ml and 59.17 ± 2.40 ng/ml (p-Value =
0.0351) Fig. 3a. Similarly, ANGPTL4 was also increased
in the obese subjects compared to non-obese (154.88 ±
6.64 ng/ml vs 136.19 ± 5.92 ng/ml respectively, p-Value =
0.0375) Fig. 3b. Finally, ANGPTL8 showed a similar
trend where its level was higher in the obese subjects
(1150.04 ± 81.39 pg/ml compared to 775.54 ± 70.77 pg/ml
for the non-diabetics, p-Value = 0.0007) Fig. 3c.
ANGPTL3, 4 and 8 gene expression level in adipose tissue
ANGPTL3, 4 and 8 gene expression level in adipose tis-
sue was examined using qRT-PCR. Unlike its plasma
level, ANGPTL3 gene expression level was not changing
Fig. 3 Circulation level of ANGPTL3, 4 and 8 in non-diabetic subjects
in accordance to their obesity level measured by ELISA. a Circulation
level of ANGPTL3 in non-obese vs obese non-diabetic subjects.
b Circulation level of ANGPTL4 in non-obese vs obese non-diabetic
subjects. c Plasma level of ANGPTL8 in non-obese vs obese
non-diabetic subjects
Fig. 4 ANGPTL3, 4 and 8 adipose tissue expression level in all
subjects. a Gene expression level of ANGPTL3 in adipose tissue
extracted from non-diabetic and T2D subjects as measured by
qRT-PCR. b Gene expression level of ANGPTL4 in adipose tissue
extracted from non-diabetic and T2D subjects as measured by qRT-PCR.
c Gene expression level of ANGPTL8 in adipose tissue extracted from
non-diabetic and T2D subjects as measured by qRT-PCR
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in the adipose tissue extracted from either T2D or non-
diabetic subjects (p-Value = 0.356) Fig. 4a. However,
ANGPTL4 level showed a two fold increase in T2D sub-
jects compared to the non-diabetic subjects as shown in
Fig. 4b (p-Value = 0.018). Similarly, ANGPTL8 showed
around two fold increases in its gene expression level in
the T2D subjects compared to the non-diabetic subjects
as shown in Fig. 4c (p-Value = 0.026).
Correlation between ANGPTL8 and ANGPTL3
Spearman’s correlation showed that ANGPTL8 associated
with ANGPTL3 in the non-diabetics subjects. It showed
significant association in the non-obese (r = 0.2437,
p-Value = 0.0543). However, a stronger correlation was ob-
served between ANGPTL8 and ANGPTL3 in the obese
subjects (r = 0.418, p-Value = 0.0125), Fig. 5. On the other
hand no association was observed between ANGPTL8
and ANGPTL3 in the T2D subjects for both obese
(r = −0.1431, p-Value = 0.3733) and non-obese groups
(r = −0.200, p-Value = 0.3488) as shown in Fig. 5.
Correlation between ANGPTL8 and ANGPTL4
Unlike ANGPTL3, Spearman’s correlation showed no
association between ANGPTL8 and ANGPTL4 in the
non-diabetics non-obese subjects (r = 0.0997, p-Value =
0.4186) as well as the non-obese T2D subjects (r = 0.3156,
p-Value = 0.1088) Fig. 6. Nonetheless, it was significantly
associated with ANGPTL4 in both obese non-diabetics
(r = 0.3322, p-Value = 0.0316) and obese T2D subjects
(r = 0.3161, p-Value = 0.0211) as shown in Fig. 6.
Discussion
In order to investigate the relationship between ANGPTL3,
4 and 8, we measured their expression level in plasma and
adipose tissue in T2D and non-diabetic subjects in the
whole population as well as in obese and non-obese sub-
jects. Overall, plasma level of ANGPTL 3, 4 and 8 were in-
creased in subjects with T2D compared to non-diabetic
subjects. Similarly, Obese/non-diabetic subjects showed
a significant increase in the plasma expression level of
ANGPTL3, 4 and 8 compared to non-obese subjects.
Fig. 5 Spearman’s correlation between ANGPTL8 and ANGPTL3 in both non-diabetic and diabetic subjects divided into non-obese and obese
subjects according to their BMI
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On the other hand, no significant difference was ob-
served between the plasma protein levels in obese and
non-obese T2D subjects. Similar to the protein level in
circulation, adipose tissue ANGPTL4 and 8 gene expres-
sion level showed a two fold increase in T2D subject com-
pared to non-diabetics. However, gene expression level of
ANGPTL3 was not affected. ANGPTL8 showed sig-
nificant correlation with ANGPTL3 in both obese and
non-obese groups in the non-diabetic subjects. ANGPTL4
on the other hand correlated positively with ANGPTL8
only in the obese subjects from both T2D and non-
diabetic subject groups.
The hydrophobic nature of lipids prevent them from
circulating freely in blood unless emulsified by proteins
forming lipoprotein complexes that circulate the blood
stream to function as a source of energy, structural
blocks and singling molecules [9, 28–30]. TG is an es-
sential lipid molecule that is used to provide energy for
the body [9]. It exists in circulation in the form of chylomi-
crons and very low density lipoprotein (VLDL). Chylomi-
crons are formed, after eating, in the villi of the duodenum
and secreted in the blood stream while VLDL are formed,
in the fasting state, by the liver and released in blood stream
[3, 31]. LPL is a key enzyme in the hydrolysis of these lipo-
proteins as well as the uptake of free fatty acids into various
tissues [9, 32, 33]. Due to the important role of this enzyme
in regulating lipoprotein metabolism and tissue specific
utilization of lipids, its activity is carefully regulated in both
the fasting and the fed state by various interacting proteins
such as members of the ANGPTL protein family [7–9, 16].
In the fasting state ANGPTL4 expression is induced
through the action of the PPAR gamma transcription factor
that is induced by fatty acids released from TG hydrolysis
[7]. During the fasting condition LPL activity is inhibited in
white adipose tissue and activated in cardiac and skeletal
muscles to increase TG hydrolysis in these tissues [16].
Similarly, ANGPTL3 and 8 play a critical role in regulating
the TG plasma level particularly under feeding condition;
where more of the TG is directed toward the adipose tissue
for storage [16]. Their inhibition of LPL activity occurs as a
result of their interaction. Studies however have shown that
unlike ANGPTL4 and 8, ANGPTL3 is not nutritionally
Fig. 6 Spearman’s correlation between ANGPTL8 and ANGPTL4 in both non-diabetic and diabetic subjects divided into non-obese and obese
subjects according to their BMI
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regulated [12]. Therefore, it has been suggested that
ANGPTL3 activity is rather regulated through ANGPTL8
that is in turn regulated by nutrition [12]. Our data shows
that the three ANGPTL proteins studied are increased in
obesity, highlighting the possibility that these proteins
might be involved and perhaps responsible for the in-
creased TG plasma levels in obese and T2D subjects. Fur-
ther follow up studies into their mechanism of action are
ought to uncover their pathophysiological role in these
diseases.
Due to their role in regulating plasma lipid content
and nutrient sensing, therapeutic modulation of the ac-
tivity of ANGPTL3, 4 and 8 is currently under consider-
able investigation as potential targets in the treatment of
dyslipidemia [7–9]. For example, monoclonal antibodies
targeting ANGPTL4 have been used in animal models
and resulted in reduced TG level as well as higher LPL
activity [7]. Similarly ANGPTL3 specific antibodies were
responsible for reduced plasma TG in both mice and
monkeys [34–36]. A recent study, by Fu et al. showed
that targeting ANGPTL8 using monoclonal antibodies
in mice resulted in reduced TG level and reduced LPL
activity in both heart and skeletal muscles but not in
white adipose tissue [37]. Our data further highlights the
potential differential interaction between ANGPTL8
with ANGPTL3 and 4. This provides more knowledge
about their role and how they are affected by various
metabolic diseases leading to better understanding of
their biological significance as well as improving their
drug targeting abilities. Our findings that ANGPTL4 and
8 positively associate with each other may be contradict-
ory as they are induced at different nutritional states;
fasting and feeding respectively. However, this could be
partially explained by a recent model based on animal
data proposed by Zhang called ANGPTL3-4-8 model
[16]. In this model, it’s proposed that these three pro-
teins regulate LPL in a tissue specific manner according
to the feeding status. In this model, it has been sug-
gested that ANGPTL4 is induced in the fasting state to
inhibit LPL in WAT directing TG to cardiac and skeletal
muscles [16]. Whereas; during feeding, ANGPTL8 is in-
duced, which acts through the interaction with ANGPTL3
to inhibit LPL activity in cardiac and skeletal muscles
directing TG to adipose tissues for storage.
One of the main limitations of this study is the cross
sectional design, which does not allow us to establish
the biological role of the studied proteins in the develop-
ment of diabetes. However, due to their well-known
function in lipid regulation, it is assumed that their in-
crease in obesity will lead to dyslipidemia that will con-
tribute to the increased insulin resistance and eventually
lead to the development of metabolic diseases like T2D.
Another limitation was the use of gene expression data
from adipose tissue. It would have been more appropriate
to study the protein expression instead of the gene expres-
sion, but due to the scarcity of the adipose tissues that
were extracted from volunteers, only gene expression was
possible.
Conclusions
In conclusion, we have comprehensively investigated the
association between ANGPTL3, 4 and 8 in obesity and
T2D in plasma and adipose tissue showing for the first
time that ANGPTL 4 and 8 are increased in human
subjects with T2D compared to non-diabetic subjects.
ANGPTL3 on the other hand was only increased in cir-
culation but not adipose tissues. Obese subjects had
higher level of ANGPTL3, 4 and 8 compared to non-obese
in the non-diabetic subjects. However, their expression in
T2D subjects was not affected by obesity. ANGPTL3 was
associated with ANGPTL8 in the non-diabetic subjects,
whereas, ANGPTL4 was associated with ANGPTL8 in the
obese subjects regardless of their diabetes status. Finally,
ANGPTL3, 4 and 8 are impotent regulators of lipid
metabolism and they offer potential therapeutic targets
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